In Thursday’s Wall Street session, Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) shares traded at $10.39, up 3.18% from the previous session.
BCRX stock price is now 24.14% away from the 50-day moving average and 30.18% away from the 200-day moving average. The market capitalization of the company currently stands at $2.17B.
With the price target of $20, Cantor Fitzgerald recently initiated with Overweight rating for Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). On February 25, 2025, Wedbush recently initiated its ‘Outperform’ rating on the stock quoting a target price of $15, while ‘JP Morgan’ rates the stock as ‘Overweight’
In other news, Hutson Nancy J, Director sold 7,000 shares of the company’s stock on Dec 13 ’24. The stock was sold for $52,780 at an average price of $7.54. Upon completion of the transaction, the Director now directly owns 86,638 shares in the company, valued at $0.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13 ’24, Director Hutson Nancy J bought 7,000 shares of the business’s stock. A total of $52,584 was incurred on buying the stock at an average price of $7.51. A total of 4.19% of the company’s stock is owned by insiders.
During the past 12 months, Biocryst Pharmaceuticals Inc has had a low of $5.92 and a high of $11.11. The fifty day moving average price for BCRX is $8.3698 and a two-hundred day moving average price translates $7.98115 for the stock.
The latest earnings results from Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was released for 2025-03-31. The company reported revenue of $145.53 million for the quarter, compared to $92.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 56.89 percent.
